BioPharmSignal logoBioPharmSignal

Biotech News

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Intellia (NTLA)IntelliaEarnings

Presented positive Phase 3 HAELO topline clinical data for lonvo-z in HAE; initiated rolling BLA submission; anticipate U.S. launch in first half of 2027 Recently resumed patient screening in MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z in ATTR-CM and ATTRv-PN, respectively Including

Related news

NTLAIntellia2026-08-06 11:00 EST

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

NTLAIntellia2026-07-30 12:00 EST

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

SGMOSangamo Therapeutics, Inc.2026-05-14 20:01 EST

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

SRPTSarepta Therapeutics2026-05-06 20:05 EST

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

CRSPCRISPR Therapeutics2026-05-04 20:30 EST

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

SRPTSarepta Therapeutics2026-08-05 20:05 EST

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

CRSPCRISPR Therapeutics2026-08-03 20:15 EST

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

SANASana Biotechnology2026-05-11 20:05 EST

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

ABEOAbeona Therapeutics2026-05-04 12:30 EST

Abeona Therapeutics® Announces Date of First Quarter Financial Results

OCGNOcugen2026-04-29 11:02 EST

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

View all latest news

Intellia

In Vivo CRISPR Gene Editing Intellia Therapeutics develops potentially one-time medicines using CRISPR-based gene editing. Its lead programs edit disease-causing genes directly inside the body through systemically delivered therapies. Hereditary Angioedema Lonvoguran ziclumeran, or lonvo-z, is an in vivo gene-editing candidate designed...

Recent company news

NTLAIntellia2026-08-07 20:01 EST

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NTLAIntellia2026-08-06 11:00 EST

Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

NTLAIntellia2026-07-30 12:00 EST

Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates

NTLAIntellia2026-07-06 20:05 EST

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NTLAIntellia2026-06-13 11:30 EST

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Stock data

Close
11.24 USD
Market cap
1.83B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States